Canopy Growth/$CGC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Canopy Growth
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
Ticker
$CGC
Sector
Health
Primary listing
Employees
960
Headquarters
Smiths Falls, Canada
Website
Canopy Growth Metrics
BasicAdvanced
$379M
-
-$2.76
2.08
-
Price and volume
Market cap
$379M
Beta
2.08
52-week high
$7.21
52-week low
$0.77
Average daily volume
13M
Financial strength
Current ratio
3.075
Quick ratio
1.965
Long term debt to equity
63.169
Total debt to equity
67.038
Interest coverage (TTM)
-0.79%
Profitability
EBITDA (TTM)
-5.698
Gross margin (TTM)
27.83%
Net profit margin (TTM)
-186.42%
Operating margin (TTM)
-18.05%
Effective tax rate (TTM)
-0.24%
Revenue per employee (TTM)
$210,320
Management effectiveness
Return on assets (TTM)
-2.83%
Return on equity (TTM)
-101.08%
Valuation
Price to revenue (TTM)
1.068
Price to book
0.91
Price to tangible book (TTM)
1.25
Price to free cash flow (TTM)
-2.206
Free cash flow yield (TTM)
-45.33%
Free cash flow per share (TTM)
-0.716
Growth
Revenue change (TTM)
-4.24%
Earnings per share change (TTM)
-58.82%
3-year revenue growth (CAGR)
-16.15%
10-year revenue growth (CAGR)
55.07%
3-year earnings per share growth (CAGR)
-62.24%
10-year earnings per share growth (CAGR)
9.78%
What the Analysts think about Canopy Growth
Analyst ratings (Buy, Hold, Sell) for Canopy Growth stock.
Bulls say / Bears say
Excluding divested operations, Canopy Growth's Q3 FY2025 net revenue rose 8% year-over-year to C$74.8 million, driven by strength in its Canadian medical cannabis segment, Storz & Bickel vaporizers, and international markets, underscoring its core operational momentum. (BNN Bloomberg)
Hemp-derived THC beverages are projected to exceed US$1 billion in U.S. sales in 2025, and Canopy’s U.S. hemp-derived product line is well positioned to capture market share in this rapidly growing subsegment. (Reuters)
Germany's medical cannabis market is forecast to grow approximately 14% annually through 2030, and Canopy's established presence via Storz & Bickel and its medical cannabis offerings in Germany positions it to capitalize on this high-growth opportunity. (Reuters)
New U.S. tariffs on cannabis-related imports, including vape hardware and packaging materials, will raise input costs and compress already thin margins, contributing to a 5–10% drop in Canopy's share price post-announcement. (Reuters)
The cannabis industry faces oversupply, falling prices, and stalled regulatory reforms in North America that are eroding investor sentiment and may limit Canopy’s access to capital in the near term. (Reuters)
In Q4 FY2025, Canopy Growth's net revenue fell 11% year-over-year to C$65 million and it reported a C$1.43 per share loss versus an estimated C$0.47, highlighting persistent top-line weakness and an earnings shortfall. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 25 Jul 2025.
Canopy Growth Financial Performance
Revenues and expenses
Canopy Growth Earnings Performance
Company profitability
Canopy Growth News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Canopy Growth stock?
Canopy Growth (CGC) has a market cap of $379M as of August 13, 2025.
What is the P/E ratio for Canopy Growth stock?
The price to earnings (P/E) ratio for Canopy Growth (CGC) stock is 0 as of August 13, 2025.
Does Canopy Growth stock pay dividends?
No, Canopy Growth (CGC) stock does not pay dividends to its shareholders as of August 13, 2025.
When is the next Canopy Growth dividend payment date?
Canopy Growth (CGC) stock does not pay dividends to its shareholders.
What is the beta indicator for Canopy Growth?
Canopy Growth (CGC) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.